CLINICAL TRIALS PROFILE FOR THERMAZENE

All Clinical Trials for THERMAZENE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05073172 ↗	StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients	Not yet recruiting	Oregon Health and Science University	N/A	2021-11-15	This clinical trial studies the effect of StrataXRT in preventing and treating radiation dermatitis in breast cancer or head and neck cancer patients. Radiotherapy is often associated with multiple side effects. These side effects can cause patient injury and make it difficult to complete treatment. For example, radiation dermatitis or skin damage may result in severe skin peeling and skin irritation. Depending on the location of radiation, the skin damage can cause problems and be tough to heal. This trial aims to see whether StrataXRT may help to prevent dermatitis after radiation therapy.
NCT05073172 ↗	StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients	Not yet recruiting	OHSU Knight Cancer Institute	N/A	2021-11-15	This clinical trial studies the effect of StrataXRT in preventing and treating radiation dermatitis in breast cancer or head and neck cancer patients. Radiotherapy is often associated with multiple side effects. These side effects can cause patient injury and make it difficult to complete treatment. For example, radiation dermatitis or skin damage may result in severe skin peeling and skin irritation. Depending on the location of radiation, the skin damage can cause problems and be tough to heal. This trial aims to see whether StrataXRT may help to prevent dermatitis after radiation therapy.

Clinical Trial Conditions for THERMAZENE

Condition Name

Condition Name for THERMAZENE
Intervention	Trials
Breast Carcinoma	1
Head and Neck Carcinoma	1

Condition MeSH

Condition MeSH for THERMAZENE
Intervention	Trials
Carcinoma	1
Breast Neoplasms	1
Radiodermatitis	1
Dermatitis	1

Clinical Trial Locations for THERMAZENE

Trials by Country

Trials by Country for THERMAZENE
Location	Trials
United States	1

Trials by US State

Trials by US State for THERMAZENE
Location	Trials
Oregon	1

Clinical Trial Progress for THERMAZENE

Clinical Trial Phase

Clinical Trial Phase for THERMAZENE
Clinical Trial Phase	Trials
N/A	1

Clinical Trial Status

Clinical Trial Status for THERMAZENE
Clinical Trial Phase	Trials
Not yet recruiting	1

Clinical Trial Sponsors for THERMAZENE

Sponsor Name

Sponsor Name for THERMAZENE
Sponsor	Trials
Oregon Health and Science University	1
OHSU Knight Cancer Institute	1

Sponsor Type

Sponsor Type for THERMAZENE
Sponsor	Trials
Other	2

THERMAZENE Market Analysis and Financial Projection

Last updated: May 9, 2026

THERMAZENE: Clinical Trials Update and Market Analysis with Forecast

What is THERMAZENE’s current clinical position?

No reliable, citable clinical-trials record or development-stage identifier for “THERMAZENE” is available in the sources required to produce a complete, accurate trials update. Without a validated compound identifier (USAN/INN, sponsor, mechanism, CAS, or trial registry ID), the clinical-trials status, enrollment, endpoints, and timelines cannot be confirmed.

What do registries show about THERMAZENE’s study activity and results?

No verifiable trial set for “THERMAZENE” can be matched to a specific investigational product using the level of traceability needed for an investment-grade update (trial NCT numbers, registry entries, protocol identifiers, sponsor names, and outcome publications).

What is THERMAZENE’s patent and exclusivity landscape?

No citable patent family, priority filing, jurisdictional coverage, or regulatory exclusivity package can be tied to “THERMAZENE” as a specific asset. Without a confirmed patent family (publication numbers and legal status), timeline-based market projection cannot be anchored.

What is THERMAZENE’s market size, uptake profile, and pricing power?

A quantitative market model requires a confirmed product identity plus a mapped indication set (e.g., dermatology, oncology, respiratory), target mechanism, comparator landscape, label geography, and payer coverage assumptions. These inputs cannot be validated for “THERMAZENE” from citable sources. A forecast would risk mixing unrelated molecules that share a trade or development name.

Market projection framework that cannot be parameterized

The following forecast inputs are missing because THERMAZENE cannot be mapped to a unique, citable drug identity:

Forecast input	Required proof artifact	Status for THERMAZENE
Indication(s) and target label	Trial endpoints, FDA/EMA submission documents	Not citable
Current phase and readout dates	NCT/CTRI/DRKS/EudraCT listings, press releases	Not citable
Competitor set and standard of care	Label data, guideline references	Not citable
Pricing and reimbursement	WAC, CMS/HTA benchmarks, payer policy	Not citable
Exclusivity duration	Patent numbers, listings, regulatory exclusivities	Not citable

Key Takeaways

• THERMAZENE cannot be uniquely identified in citable clinical, patent, or regulatory sources under the name provided, so a clinical trials update and market projection cannot be produced without contaminating results.
• An investment-grade update requires a verifiable product identity (trial registry linkage and patent family mapping). Those artifacts are not present for “THERMAZENE” here.

FAQs

1. Can you provide THERMAZENE clinical trial phase, enrollment, and endpoints?
   Not with the current, unverified product name because no citable trial registry entries can be matched to a unique investigational product.

2. Can you forecast peak sales for THERMAZENE?
   Not without a validated indication set, approved geography, and a verified comparator landscape, none of which can be tied to THERMAZENE in citable sources.

3. Is THERMAZENE in Phase 2 or Phase 3?
   A phase call cannot be made without a linked trial record (e.g., NCT/registry number) tied to the same asset.

4. What patents protect THERMAZENE?
   Patent mapping cannot be provided because no patent family can be confirmed to the asset name “THERMAZENE.”

5. When could THERMAZENE launch?
   Launch timing cannot be projected without confirmed regulatory status, trial readouts, and exclusivity constraints that cannot be validated for the asset under the provided name.

References

[1] ClinicalTrials.gov. (n.d.). Search results for THERMAZENE. https://clinicaltrials.gov/
[2] World Intellectual Property Organization. (n.d.). PATENTSCOPE search. https://patentscope.wipo.int/
[3] FDA Drugs@FDA. (n.d.). Search results for THERMAZENE. https://www.accessdata.fda.gov/scripts/cder/daf/